Amid a flurry of dealmaking activity to start 2024, Allorion Therapeutics Inc., a 2020 startup based in Natick, Mass., and Guangzhou, China, has been extra busy. Two days after disclosing a potential $540 million deal with Astrazeneca plc, Allorion inked a licensing agreement with Avenzo Therapeutics Inc. that could total more than $1 billion.
Amid a flurry of dealmaking activity to start 2024, Allorion Therapeutics Inc., a 2020 startup based in Natick, Mass., and Guangzhou, China, has been extra busy. Two days after disclosing a potential $540 million deal with Astrazeneca plc, Allorion inked a licensing agreement with Avenzo Therapeutics Inc. that could total more than $1 billion.
Announcing two licensing deals with Swiss pharma giant Novartis AG, Shanghai-based Argo Biopharmaceutical Co. Ltd. said on Jan. 7 that it stands to gain up to $4.165 billion for two of its cardiovascular assets combined. Marking the “first significant overseas out-licensing transaction in the RNAi field from a Chinese biotech company,” the deal includes an up-front payment of $185 million from Novartis to Argo.
Announcing two licensing deals with Swiss pharma giant Novartis AG, Shanghai-based Argo Biopharmaceutical Co. Ltd. said on Jan. 7 that it stands to gain up to $4.165 billion for two of its cardiovascular assets combined. Marking the “first significant overseas out-licensing transaction in the RNAi field from a Chinese biotech company,” the deal includes an up-front payment of $185 million from Novartis to Argo.
Amid a flurry of dealmaking activity to start 2024, Allorion Therapeutics Inc., a 2020 startup based in Natick, Mass., and Guangzhou, China, has been extra busy. Two days after disclosing a potential $540 million deal with Astrazeneca plc, Allorion inked a licensing agreement with Avenzo Therapeutics Inc. that could total more than $1 billion.
Allorion Therapeutics Inc. has entered into an exclusive option and global license agreement with Astrazeneca plc to develop and commercialize a novel epidermal growth factor receptor (EGFR) L858R mutated allosteric inhibitor.
Allorion Therapeutics Inc. could receive $40 million in up-front and near-term payments from Astrazeneca plc in the companies’ exclusive option and global license deal. The two plan to develop and commercialize an L858R mutated allosteric inhibitor for treating EGFR inhibitor-mutant non-small-cell lung cancer.
